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The bromodomain and extraterminal (BET) protein
BRD4 can physically interact with the Mediator com-
plex, but the relevance of this association to the ther-
apeutic effects of BET inhibitors in cancer is unclear.
Here, we show that BET inhibition causes a rapid
release of Mediator from a subset of cis-regulatory
elements in the genome of acute myeloid leukemia
(AML) cells. These sites of Mediator eviction were
highly correlated with transcriptional suppression
of neighboring genes, which are enriched for targets
of the transcription factor MYB and for functions
related to leukemogenesis. A shRNA screen of Medi-
ator in AML cells identified the MED12, MED13,
MED23, and MED24 subunits as performing a similar
regulatory function to BRD4 in this context, including
a shared role in sustaining a block in myeloidmatura-
tion. These findings suggest that the interaction be-
tween BRD4 andMediator has functional importance
for gene-specific transcriptional activation and for
AML maintenance.
INTRODUCTION
The bromodomain and extraterminal (BET) protein BRD4 is
a therapeutic target in several human malignancies, including
acute myeloid leukemia (AML) (Shi and Vakoc, 2014). While the
efficacy of BET inhibitors in mouse models has motivated
ongoing clinical trials in hematologic malignancies (e.g., https://
clinicaltrials.gov: NCT01713582), the underlyingmolecularmech-
anismofBRD4 function in supportingcancerprogression remains
poorly understood. BRD4uses tandembromodomainmodules to
recognize acetyl-lysine side chains on histones and transcription
factors (TFs), thereby localizing to hyper-acetylated promoter and
enhancer regions of the genome (Dey et al., 2003; Roe et al.,
2015). Moreover, chemical inhibitors of BET bromodomains
(e.g., JQ1 and IBET) cause a global release of BRD4 from the
genome (Filippakopoulos et al., 2010; Nicodeme et al., 2010).
When bound to chromatin, BRD4 recruits various proteins,
including P-TEFb, JMJD6, and NSD3, to activate its target genesThis is an open access article under the CC BY-N(Jang et al., 2005; Liu et al., 2013; Rahmanet al., 2011; Shen et al.,
2015; Yang et al., 2005). Proteomic analyses of BRD4 complexes
have revealed numerous other associated factors (Dawson et al.,
2011; Jang et al., 2005; Rahman et al., 2011); however, the rele-
vance of such interactions to the cancer maintenance function
of BRD4 is largely unstudied.
A physical association between the Mediator complex and
BRD4 has been shown in several prior studies (Donner et al.,
2010; Jang et al., 2005; Jiang et al., 1998; Wu and Chiang,
2007). Mediator is a30-subunit coactivator complex that inter-
acts with TFs and participates in the recruitment and activation
of RNA polymerase II (Pol II) (Allen and Taatjes, 2015; Malik
and Roeder, 2010). Because the precise binding surface that
links BRD4 and Mediator has yet to be defined, the functional
importance of this physical interaction is currently unclear. In
support of a functional link between BRD4 and Mediator, it has
been observed that both factors colocalize at super-enhancers
(clusters of highly active enhancers) and BET inhibition can per-
turb BRD4 andMediator occupancy at such sites (DiMicco et al.,
2014; Love´n et al., 2013). In addition, embryonic stem cells
require both BRD4 and Mediator to maintain Oct4 expression
and the pluripotent cell state (Di Micco et al., 2014; Kagey
et al., 2010; Wu et al., 2015). However, a recent study has shown
that the kinase subunits of Mediator (CDK8 and CDK19) function
in opposition to BRD4 to repress super-enhancer-associated
genes (Pelish et al., 2015). Taken together, these prior studies
raise two key questions: (1) at what locations of the genome is
Mediator released following BET inhibitor treatment? and (2)
does perturbation of Mediator contribute to the transcriptional
effects and therapeutic activity of BET inhibition in cancer and
other diseases?
Here, we show that JQ1 causes a dramatic loss of Mediator
occupancy at a subset of cis elements in the genome of AML
cells, which only partially overlaps with the location of super-
enhancers. Notably, Mediator eviction tracked closely with the
sensitivity of gene expression to JQ1, which suggests that
release of Mediator from the genome contributes to the tran-
scriptional effects of BET inhibition. In support of this model, a
Mediator-focused short hairpin RNA (shRNA) screen performed
in AML cells revealed that BRD4 andMediator coordinate a com-
mon gene-regulatory network that maintains a blocked state of
differentiation. Because Mediator is preferentially evicted by
JQ1 near genes that promote leukemogenesis, our findingsCell Reports 15, 519–530, April 19, 2016 ª2016 The Authors 519
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
implicate release of Mediator from the genome as a contributor
to the therapeutic activity of BET inhibition in AML.
RESULTS
The Mediator Complex Is Released from the Leukemia
Genome in a Variable Manner following JQ1 Exposure
We tested the hypothesis that BET inhibition with JQ1 elicits anti-
leukemia effects by interfering with the Mediator complex. To
this end, we first performed chromatin immunoprecipitation
sequencing (ChIP-seq) analysis comparing the chromatin occu-
pancy profiles of BRD4 and MED1 (a Mediator subunit) in cells
derived from a mouse model of MLL-AF9;NrasG12D AML (the
RN2 cell line; Zuber et al., 2011a). This revealed that BRD4 and
MED1 colocalized across the AML genome in a pattern that
overlapped with H3K27 hyper-acetylation (Figure 1A). Moreover,
the tag counts of MED1 and BRD4 at each individual peak were
highly correlated (R2 = 0.91; Figure S1A). The close correlation
between BRD4 andMED1 across the AML genome is consistent
with a physical interaction between these regulators occurring in
this cell type.
Next, we performed ChIP-seq analysis of BRD4 and MED1 in
RN2 cells following a 2-hr exposure to 500 nM JQ1 or to vehicle
control (DMSO). Transcription of the Myc proto-oncogene in
RN2 cells is highly sensitive to JQ1 and is regulated by BRD4
via a super-enhancer (also known as E1–E5) located 1.7 mega-
bases downstream of the Myc promoter (Shi et al., 2013; Zuber
et al., 2011c). As expected, we found that BRD4 was completely
evicted from this location by JQ1 (Figure 1B). In addition, we
observed an equally dramatic reduction of MED1 occupancy
at this same region (Figure 1B). To ensure that the entirety of
the Mediator complex was released from this site, we com-
plemented our ChIP-seq studies with ChIP-qPCR analysis of
BRD4, MED1, MED12, and MED23, which revealed parallel re-
ductions of all four factors at the Myc super-enhancer following
JQ1 treatment (Figures S1B–S1G). Because MED1, MED12, and
MED23 reside in distinct modules of Mediator (middle, kinase,
and tail, respectively), this result suggests that the entire Medi-
ator complex was released following BET bromodomain
inhibition.
Because prior studies have shown that BET inhibition reduces
MED1 occupancy at several super-enhancers (Di Micco et al.,
2014; Love´n et al., 2013), we considered whether the release
of Mediator from the genome in RN2 cells was restricted to
this class of elements. For this purpose, we applied the rank
ordering of super-enhancers (ROSE) algorithm to MED1 ChIP-
seq data to define super-enhancers in RN2 cells and inspected
the sensitivity of MED1 at these locations to JQ1-mediated evic-
tion (Figure 1C).Cdk6 has previously been implicated as a BRD4
target gene in AML and is regulated by an intronic super-
enhancer (Dawson et al., 2011; Roe et al., 2015). Similar to the
Myc locus, we observed reductions of both BRD4 and MED1
at the Cdk6 super-enhancer following BET inhibition (Figure 1D).
However, we unexpectedly observed that not all super-en-
hancers were susceptible to JQ1-mediated MED1 eviction.
The Lrrfip1 gene harbors a promoter-proximal super-enhancer
that displayed no apparent reduction of MED1 following expo-
sure to JQ1 (Figures 1C and 1E). As another example, a large520 Cell Reports 15, 519–530, April 19, 2016domain of MED1 occupancy at the HoxA locus qualifies as a
super-enhancer (Figure 1C) and yet is entirely unaffected by
JQ1 (Figure 1F). Conversely, we found that MED1 was released
from several regions that fell below the threshold of being
called as super-enhancers, such as intronic locations of Mgat5
(Figures 1C and 1G). Across all genomic sites, we observed a
weak correlation between the magnitude of MED1 and BRD4
release following JQ1 exposure (R2 = 0.13; Figure S1H). How-
ever, we also identified a small subset of sites that exhibit
severe decreases of both MED1 and BRD4 following JQ1 treat-
ment (Figure S1H). Collectively, these findings show that JQ1
causes variable Mediator release at cis-regulatory elements in
AML cells.
JQ1-Induced Mediator Eviction Correlates with
Transcriptional Suppression
Next, we sought to determine whether MED1 eviction was corre-
lated with the gene expression changes caused by JQ1. 10,604
reproducible MED1 peaks were defined using model-based
analysis of ChIP-seq (MACS) software and rank ordered based
on the average fold change of MED1 tag counts following expo-
sure to JQ1 in two biological replicates (Zhang et al., 2008). This
revealed that the constituent MED1 peaks within theMyc super-
enhancer were outliers in the RN2 genome with regard to the
severity of MED1 loss (Figure 2A). This result was striking,
because Myc is also among the most-downregulated mRNAs
in AML cells after JQ1 treatment (Dawson et al., 2011; Zuber
et al., 2011c; Figure 2B). Furthermore, the magnitude of MED1
loss at peaks located near Cdk6, Lrrfip1, Hoxa9, and Mgat5
correlated well with the relative effect of JQ1 on expression of
these genes (Figures 2A and 2B). This analysis raised the possi-
bility that release of Mediator from the genomemay contribute to
the effect of BET inhibition on transcription.
To test this hypothesis in a systematic manner, we defined
200 MED1 peaks in RN2 cells that exhibited the greatest sensi-
tivity to JQ1 (Figures 2A and S2A; Table S1). We next applied
the genomic regions enrichment of annotations tool (GREAT)
to link each of these peaks to the nearest expressed gene
as its presumed target (McLean et al., 2010; Table S2). We
performed an analogous GREAT analysis to link each super-
enhancer in RN2 cells to the nearest expressed gene (Figure 1C;
Table S2). These two gene sets were then independently evalu-
ated in RNA-seq data derived from RN2 cells treated with
500 nM JQ1 for 6 hr (Roe et al., 2015). Consistent with prior
observations, we found that super-enhancer genes were more
suppressed, on average, by JQ1 than randomly chosen ex-
pressed genes (Figure 2C; Love´n et al., 2013). However, we
found that genes located near JQ1-sensitive MED1 peaks
were suppressed to a significantly greater extent than genes
located in proximity to super-enhancers (Figures 2C). This result
prompted us to consider whether super-enhancers encompass
two distinct classes of cis elements that differ with regard to their
sensitivity to JQ1-mediated perturbation. Indeed, we found that
75 of the 178 super-enhancers in RN2 cells overlapped with at
least one JQ1-sensitive MED1 peak (Figure 2D), and only this
subset of super-enhancers was associated with transcriptional
suppression by JQ1 (Figure 2E). Importantly, this result suggests
that a large fraction of super-enhancers (103 out of 178) are not
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Figure 1. The Mediator Complex Is Released from the AML Genome in a Variable Manner following JQ1 Exposure
(A) Density plot of BRD4, MED1, and H3K27Ac ChIP-seq datasets in murine MLL-AF9/NrasG12D AML. Data are centered on 5,135 high-confidence BRD4-
occupied elements (Roe et al., 2015). Each row represents a 10-kilobase interval surrounding a single peak.
(B) ChIP-seq occupancy profiles of BRD4 and MED1 at the Myc locus following a 2-hr treatment with DMSO (vehicle) or 500 nM JQ1.
(C) 178 super-enhancers defined by MED1 occupancy using the ROSE algorithm.
(D) ChIP-seq occupancy profiles of BRD4 and MED1 at the Cdk6 locus following a 2-hr treatment with DMSO or 500 nM JQ1.
(E) ChIP-seq occupancy profiles of BRD4 and MED1 at the Mgat5 locus following a 2-hr treatment with DMSO or 500 nM JQ1.
(F) ChIP-seq occupancy profiles of BRD4 and MED1 at the Lrrfip1 locus following a 2-hr treatment with DMSO or 500 nM JQ1.
(G) ChIP-seq occupancy profiles of BRD4 and MED1 at the HoxA cluster following a 2-hr treatment with DMSO or 500 nM JQ1.
See also Figure S1 and Table S4.
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perturbed by JQ1 and appear to be unrelated to the transcrip-
tional effects of BET inhibition.
Next, we evaluated whether JQ1-sensitive MED1 peaks
harbor unique sequences features. A set of hematopoietic TFs
(C/EBPa, C/EBPb, ERG, FLI1, MYB, and PU.1) has been shown
to facilitate BRD4 recruitment in AML cells (Roe et al., 2015).
When compared to all MED1 peaks, JQ1 sensitivity was associ-
ated with a higher motif density and genomic occupancy of MYB
and, to a lesser extent, C/EBPa and C/EBPb (Figures 2F, S2C,
and S2D). In contrast, sequence motifs and overall occupancy
for PU.1, ERG, and FLI1 were not dramatically elevated at
JQ1-sensitive versus JQ1-insenstive MED1 peaks. We also
evaluated whether the genes located near JQ1-sensitive MED1
peaks were enriched for any particular biological or molecular
pathways. For this purpose, we used GREAT to compare the
ontology of genes located near 200 JQ1-sensitive MED1 peaks
with genes located near 200 randomMED1 peaks. This revealed
that Mediator was released disproportionately near genes
involved in leukemia pathogenesis (Figure 2G). In this same anal-
ysis, MYB was the most-enriched TF network among the JQ1-
sensitive MED1 peaks, in agreement with the higher relative level
of MYB occupancy at this class of cis elements (Figures 2F and
2G). These results suggest that Mediator is preferentially evicted
by JQ1 near MYB targets genes and near genes involved in the
pathogenesis of leukemia.
Knockdown of Select Mediator Tail and Kinase Module
Subunits Triggers Differentiation of Leukemic Blasts
The genomic correlations described above support a model in
which BRD4 and Mediator function as linked coactivators for
a common set of target genes in AML cells. One prediction of
this model is that targeting of specific subunits of Mediator
may lead to similar cellular phenotypes and transcriptional
changes as observed when targeting BRD4. Inhibition of BRD4
with either JQ1 or shRNA impairs the proliferation of RN2 cells
and triggers differentiation of leukemic blasts into macro-
phage-like cells, which express higher levels of Mac1 and lower
levels of cKit on their cell surface (Zuber et al., 2011c). To eval-
uate the phenotypic consequences of Mediator perturbation inFigure 2. JQ1-Induced Mediator Eviction Correlates with JQ1-Induced
(A) Fold change in occupancy of MED1 at 10,604 individual MED1 peaks in AML
increasing fold change (JQ1/DMSO). The blue box highlights the 200 most-JQ
independent biological replicates.
(B) Fold change in FPKM (fragments per kilobase of transcript permillion) for 8,118
of 500 nM JQ1 treatment. The genes are ranked in order of increasing fold cha
indicated genes.
(C) Average fold change in FPKM after JQ1 treatment for all expressed genes (left)
with JQ1-sensitive MED1 peaks (right). The numbers in parentheses represent t
p value < 0.0001, the result of a Mann-Whitney test.
(D) Stratification of 178 MED1 super-enhancers based on whether or not they
overlap 1 bp).
(E) Average fold change in FPKM for genes associated with JQ1-sensitive MED1
enhancers (as delineated in D). The numbers in parentheses represent the number
p value < 0.0001, the result of a Mann-Whitney test.
(F) ChIP-seq meta-profiles for hematopoietic TF occupancy at 200 JQ1-sensitive
(G) GREAT ontology analysis binomial p values for 200 JQ1-sensitive MED1 pea
sensitive peaks are displayed alongside values for the same ontology terms in the
GREAT database.
See also Figure S2 and Tables S2 and S3.this cell type, we constructed a custom library of 190 shRNAs
targeting all of the known Mediator subunits (approximately six
shRNAs/gene; Table S3) and carried out a negative-selection
screen to identify essential subunits for cell proliferation and/or
viability. The relative growth arrest observed over 10 days in cul-
ture was quantified using GFP reporters in a competition-based
assay (Figure 3A). This screen revealed that RN2 cell proliferation
was hypersensitive to targeting of select subunits of the Medi-
ator complex. This includes components of the head (MED8,
MED28, and MED30), middle (MED9 and MED26), tail (MED16,
MED23, MED24, and MED25), and kinase (MED12 and
MED13) modules (Figures 3A and 3B). On-target knockdown of
the intended target gene of each scoring shRNA was validated
using qRT-PCR (Figure S3A). These findings confirm that several
Mediator subunits are essential for AML proliferation.
To evaluate the specificity of these growth-arrest phenotypes,
we transduced immortalized mouse embryonic fibroblast cells
(iMEFs) with shRNAs targeting each of the essential Mediator
subunits identified in the screen above and performed competi-
tion-based proliferation assays.We found that the knockdown of
MED12, MED13, MED23, and MED24 led to no apparent growth
defect in iMEFs, whereas MED8 and MED30 were each found to
be essential for iMEF growth (Figures S3B and S3C). This hetero-
geneity of growth-arrest phenotypes following perturbation of in-
dividual Mediator subunits was unrelated to the level of expres-
sion of these subunits (data not shown). Collectively, our findings
suggest that AML cell proliferation is uniquely hypersensitive
to targeting of Mediator subunits MED12, MED13, MED23, and
MED24. Interestingly, MED12 andMED23 have each been impli-
cated previously in the physical interaction with BRD4 (Jang
et al., 2005; Wang et al., 2013).
Next, we evaluated whether knockdown of specific Mediator
subunits in RN2 cells causedmyeloidmaturation in an analogous
manner to BRD4 inhibition (Zuber et al., 2011c).When expressed
conditionally via a doxycycline (dox)-regulated promoter, we
found that MED12, MED13, MED23, and MED24 shRNAs, but
not MED8 and MED30 shRNAs, altered the cell surface expres-
sion of cKit andMac1 in a manner that resembled the phenotype
provoked by BRD4 knockdown (Figures 3C and 3D). To confirmTranscriptional Suppression
following 2 hr treatment with 500 nM JQ1. The peaks are ranked in order of
1-sensitive MED1 elements. Fold changes presented are the average of two
expressed genes in AML (defined by FPKM> 5 in DMSO sample) following 6 hr
nge. The numbers in parentheses are the fold change expression rank of the
, for genes associated with super-enhancers (center), and for genes associated
he number of genes matched to the class of peaks indicated. *** represents a
overlap with at least one of the 200 JQ1-sensitive MED1 peaks (minimum
super-enhancers and for genes associated with JQ1-insensitive MED1 super-
of genesmatched to the subclass of super-enhancer indicated. *** represents a
MED1 peaks or the remaining 10,404 MED1 peaks.
ks versus 200 random MED1 peaks. Top-ranking ontology terms for the JQ1-
random peaks. Terms in parentheses represent the ontology identifiers in the
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Figure 3. Genetic Knockdown of Select Mediator Subunits Triggers Differentiation of AML Blasts
(A) Summary of negative-selection shRNA screen targeting the indicated Mediator subunits. Bars represent the average of all hairpins for each gene. Black bars
highlight subunits having at least 3-fold loss of GFP-positive cells with at least two independent hairpins. shRNAs are expressed using the LMN vector. Data are
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(C) Flow cytometric analysis of cell-surface cKit following 96 hr of doxycycline-induced expression of the indicated shRNAs. shRNAs were expressed using the
TRMPV-Neo vector. Gating was performed on GFP+/shRNA+ cell populations.
(D) Flow cytometric analysis of cell-surface Mac1 following 96 hr of doxycycline-induced expression of the indicated shRNAs. shRNAs were expressed using the
TRMPV-Neo vector. Gating was performed on GFP+/shRNA+ cell populations.
(E) Light microscopy analysis of May-Gr€unwald-Giemsa-stained RN2 cells after 96 hr of doxycycline-induced expression of the indicated shRNAs. The images
were taken with 403 objective.
See also Figure S3 and Table S3.
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Figure 4. MED12 and MED23 Are Required to Sustain Expression of BRD4, MYC, and MYB Target Gene Signatures in AML Cells
(A) Fold change in FPKM for 8,393 expressed genes in AML (defined by FPKM > 5 in shRen sample) following 48 hr of doxycycline treatment to induce two
independent shRNAs targeting Med12 (401 and 5,755) versus shRen.713. Fold change values for each gene are the average value of the independent hairpins
targeting the indicated Mediator subunit. The genes are ranked in order of increasing fold change. The numbers in parentheses represent the fold change
expression rank of the indicated genes.
(B) Fold change in FPKM for 8,393 expressed genes in AML (defined by FPKM > 5 in shRen sample) following 48 hr of doxycycline treatment to induce two
independent shRNAs targeting Med23 (678 and 4,061) versus shRen.713. Fold change values for each gene are the average value of the independent hairpins
targeting the indicated Mediator subunit. The genes are ranked in order of increasing fold change. The numbers in parentheses represent the fold change
expression rank of the indicated genes.
(C) Gene set enrichment analysis (GSEA) of shMed12 versus shRen RNA-seq using 10,379 gene sets, including all gene sets in the Molecular Signatures
Database. Signatures are ranked by their normalized enrichment scores and false discovery rate (FDR) q values according to GSEA.
(legend continued on next page)
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that differentiation was induced following Mediator subunit
knockdown, we imaged May-Gr€unwald/Giemsa-stained RN2
cells using light microscopy. Consistent with the flow cytometry
analysis, knockdown of MED12, MED13, MED23, or MED24, but
not of MED8 or MED30, led to similar morphologic changes to-
ward mature macrophages as observed with BRD4 knockdown
(Figure 3E). These findings suggest that targeting select Medi-
ator subunits can trigger differentiation of AML blasts.
shRNA-based knockdown of the homologous kinase subunits
CDK8 and CDK19 of Mediator failed to elicit proliferation arrest
of RN2 cells (Figures 3A, S3D, and S3E). However, we found
that dual shRNA-based targeting of these two kinases led to
an arrest in the proliferation of RN2 cells (Figure S3E). This result
suggests a redundant function for these two kinase subunits,
which is consistent with a recent study showing that dual
CDK8/CDK19 inhibition with cortistatin A suppressed AML cell
growth (Pelish et al., 2015).
Mediator Subunits Are Required to Sustain Expression
of BRD4 Target Genes in AML Cells
Next, we considered whether a common gene regulatory
network depends on BRD4 and Mediator for expression in
RN2 cells using RNA-seq analysis. In an analogous manner to
JQ1 treatment, knockdown of MED12 or MED23 resulted in
reducedmRNA levels ofMyc,Mgat5, andCdk6, but not of Lrrfip1
orHoxa9 (Figures 4A and 4B). To provide an unbiased evaluation
of gene signatures altered by knockdown, we performed gene
set enrichment analysis (GSEA) to interrogate a database of
10,379 gene sets (Subramanian et al., 2005). Remarkably,
several of the most-downregulated gene signatures in MED12-
or MED23-deficient RN2 cells corresponded to the target genes
of MYB, MYC, and BRD4 (Figures 4C–4F). Among the positively
enriched gene sets were those related to myeloid cell matura-
tion, consistent with the phenotypic changes observed following
MED12 and MED23 knockdown (Figures 4C–4F). Knockdown
of MED8 also led to suppression of BRD4 target genes such
as Myc; however, the global pattern of gene expression was
different from what was observed following MED12 or MED23
knockdown, consistent with the differing phenotypes upon
knockdown of these subunits (Figures S4A–S4C). GSEA re-
vealed that, while BRD4 and MYC signatures were affected by
MED8 knockdown, a number of transcriptional pathways not
suppressed by JQ1 treatment or by MED12 or MED23 shRNA(D) Gene set enrichment analysis (GSEA) of shMed23 versus shRen RNA-seq
Database. Signatures are ranked by their normalized enrichment scores and fals
(E) GSEA plots from the shMed12 RNA-seq showing enrichment of a BRD4 targe
p value), as calculated by GSEA, are provided.
(F) GSEA plots from the shMed12 RNA-seq showing enrichment of a MYC targe
p value), as calculated by GSEA, are provided.
(G) GSEA plots from the shMed12 RNA-seq showing enrichment of amyeloid diffe
(Nom p value), as calculated by GSEA, are provided.
(H) GSEA plots from the shMed23 RNA-seq showing enrichment of a BRD4 targe
p value), as calculated by GSEA, are provided.
(I) GSEA plots from the shMed23 RNA-seq showing enrichment of a MYC targe
p value), as calculated by GSEA, are provided.
(J) GSEA plots from the shMed23 RNA-seq showing enrichment of amyeloid differ
(Nom p value), as calculated by GSEA, are provided.
See also Figure S4 and Table S4.
526 Cell Reports 15, 519–530, April 19, 2016were suppressed in MED8-deficient cells (Figures S4B and
S4D). Whereas it appears that individual Mediator subunits
perform distinct transcriptional functions, our findings support
a role for the Mediator complex in supporting BRD4-dependent
gene activation.
Next, we explored the mechanism by which BRD4 and Medi-
ator regulate Pol II activity at their co-regulated target genes.
Mediator and BRD4 have each been shown to interact with the
kinase P-TEFb, comprised of CDK9 and cyclin T, which can
stimulate the release of paused Pol II near the transcriptional
start site (TSS) (Donner et al., 2010; Jang et al., 2005; Takahashi
et al., 2011; Yang et al., 2005). Using ChIP-qPCR, we found that
BET inhibition and MED12 knockdown each led to a loss of
CDK9 and Pol II from the Myc super-enhancer and gene body
(Figures 5A–5H; Table S4). Notably, the loss of Pol II near the
Myc TSS was less severe (3.7-fold for JQ1 and 1.3-fold for
shMED12) relative to the gene body (15.8-fold for JQ1 and
5.4-fold for shMED12; Figures 5D and 5H). This result is consis-
tent with BRD4 and Mediator promoting the transition of Pol II
from initiation to elongation by facilitating P-TEFb recruitment.
A recent study showed thatMediator can facilitate BRD4 chro-
matin localization in the setting of acquired resistance to BET in-
hibitors in breast cancer (Shu et al., 2016). We therefore consid-
ered whether Mediator plays a reciprocal role in stabilizing BRD4
occupancy in RN2 cells. Because MED12 and MED23 knock-
down each mimicked the phenotypic and transcriptional effects
of BRD4 inhibition, we performed BRD4 ChIP-seq following
knockdown of these subunits. This revealed that MED12 and
MED23 knockdown resulted in a modest reduction in BRD4
chromatin occupancy at the same cis elements at which MED1
is perturbed following BET inhibition (Figures S5A–S5E). This
result suggests that BRD4 and Mediator can mutually stabilize
one another’s chromatin occupancy.
DISCUSSION
The findings presented in this study support a model in which
BRD4 regulates its downstream target genes, at least in part,
via a physical interaction with the Mediator complex. We have
previously shown that BRD4 directly interacts with the short
isoform of NSD3, which acts as a bridge to recruit the CHD8
chromatin remodeler (Shen et al., 2015). In addition, BRD4 is
known to recruit P-TEFb to promote transcription elongation ofusing 10,379 gene sets, including all gene sets in the Molecular Signatures
e discovery rate (FDR) q values according to GSEA.
t gene set. Normalized enrichment scores (NESs) and nominal p values (Nom
t gene set. Normalized enrichment scores (NESs) and nominal p values (Nom
rentiation gene set. Normalized enrichment scores (NESs) and nominal p values
t gene set. Normalized enrichment scores (NESs) and nominal p values (Nom
t gene set. Normalized enrichment scores (NESs) and nominal p values (Nom
entiation gene set. Normalized enrichment scores (NESs) and nominal p values
A B
C D
E F
G H
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its target genes (Jang et al., 2005; Yang et al., 2005). Notably,
Mediator has also been shown to recruit P-TEFb to promote
transcription elongation (Donner et al., 2010; Takahashi et al.,
2011). Taken together, these observations reinforce a model in
which BRD4 acts as a scaffold that recruits multiple regulatory
machineries to cis elements bound by acetylated TFs and nucle-
osomes to promote transcription of genes that sustain the
aberrant growth and self-renewal properties of AML cells.
Our dual shRNA-targeting experiments are in agreement with
a recent study, which found that AML cells are sensitive to chem-
ical inhibition of CDK8/CDK19 with cortistatin A (Pelish et al.,
2015). In this study, it was shown that these kinases act to
restrain super-enhancer activity, thereby antagonizing the acti-
vation function of BRD4 (Pelish et al., 2015). Importantly, our
shRNA-screening results suggest that this repressive function
is likely to be confined to the CDK8/CDK19 subunits of Mediator,
whereas other subunits, including the kinase-associated subunit
MED12, are involved in supporting BRD4-dependent transcrip-
tional activation. While it is surprising to observe opposing
effects of targeting individual subunits within the same module
of the Mediator complex, other studies have also observed
contrasting phenotypic and transcriptional consequences after
knockdown of MED12 versus CDK8 subunits (Gobert et al.,
2010; Kuuluvainen et al., 2014). Nevertheless, our study and Pel-
ish et al. (2015) reinforce how distinct perturbations of Mediator
can destabilize the AML cell state.
Our study provides insights into how JQ1 exerts dispropor-
tionate effects on cancer-relevant genes while sparing house-
keeping gene expression, a property that likely underlies the
therapeutic efficacy of this agent in AML and other malignancies.
It has previously been proposed that the location of super-
enhancers harboring exceptional levels of BRD4 and Mediator
provides the molecular basis for the hypersensitivity of specific
genes to JQ1-mediated transcriptional suppression (Love´n
et al., 2013). We have shown here that the hypersensitivity
of Mediator to JQ1-mediated displacement can be uncoupled
from the pre-existing levels of Mediator occupancy, which is,
in turn, reflected in the heterogeneous sensitivity of super-
enhancer-linked genes to JQ1-mediated suppression. Our study
shows that less than half of all super-enhancers in AML cells
exhibit JQ1-mediated displacement of the Mediator complex
(Love´n et al., 2013). Importantly, our findings suggest that the
degree of Mediator eviction can serve as a useful biomarker
for revealing the critical cis elements that are functionally sup-
pressed by BET inhibition. Measurements of MED1 evictionFigure 5. BET Inhibition and MED12 Knockdown Cause Loss of CDK9
(A) ChIP-qPCR analysis of CDK9 at the Myc super-enhancer following a 2-hr tre
(B) ChIP-qPCR analysis of CDK9 across the Myc gene body following a 2-hr trea
(C) ChIP-qPCR analysis of Pol II at the Myc super-enhancer following a 2-hr trea
(D) ChIP-qPCR analysis of Pol II at theMyc gene body following a 2-hr treatment w
indicate fold change between DMSO and JQ1 ChIP-qPCR enrichment.
(E) ChIP-qPCR analysis of CDK9 at the Myc super-enhancer locus following 0- o
used.
(F) ChIP-qPCR analysis of CDK9 across the Myc gene body following 0- or 48-h
(G) ChIP-qPCR analysis of Pol II at the Myc enhancer locus following 0- or 48-hr
(H) ChIP-qPCR analysis of Pol II across the Myc gene body following 0- or 48-hr
indicate fold change between control and shMed12 ChIPs at these regions. TRMP
are presented as mean ± SEM and n = 3.
528 Cell Reports 15, 519–530, April 19, 2016following JQ1 exposure could be applied more broadly to reveal
the critical downstream genes that underlie the therapeutic
effects of BET inhibition in various cellular contexts.
Whereas BRD4 occupancy correlates genome-wide with the
occupancy of several hematopoietic TFs (Roe et al., 2015), the
sensitivity of Mediator to JQ1-mediated eviction correlates with
cis elements specifically harboring higher levels of the TF MYB.
In addition, our ontology analysis shows that genes associated
with JQ1-sensitive MED1 also enriched for the MYB target
gene network. Notably, a somatic mutation has been described
in T cell acute lymphoblastic leukemia that produces a novel
MYB-binding motif near the TAL1 gene, which leads to the for-
mation of a MED1-occupied super-enhancer (Mansour et al.,
2014). Interestingly, AML cells are known to be more sensitive
to MYB knockdown than normal myeloblasts (Zuber et al.,
2011b). Since MYB physically associates with BRD4 (Roe
et al., 2015), our results suggest that MYB function might place
unique demands on BRD4-Mediator complexes to sustain
expression of genes with leukemogenic functions, which may
contribute to the hypersensitivity of AML cell growth to BET bro-
modomain inhibition.
EXPERIMENTAL PROCEDURES
ChIP-Seq
One hundred twenty million RN2 cells were crosslinked with 1% formaldehyde
for 20 min and quenched for 10min with 0.125M glycine. Nuclear lysates were
sonicated in 20 million cell batches using a BioRuptor water bath sonicator.
Sonicated chromatin was pre-cleared using rabbit immunoglobulin G (IgG)
and agarose beads or was incubated with the BRD4 antibody for 2 hr followed
by addition of magnetic beads (BRD4 ChIP-seq inMED12/23 knockdown con-
ditions). Immunoprecipitation (IP) with the relevant antibodies was performed
overnight at 4Cwith rotation. After extensive washing as previously described
(Steger et al., 2008), crosslinks were reversed overnight at 65C. DNA was
treatedwith RNaseA and ProteinaseK and purified using theQIAGENPCRpu-
rification kit. Libraries were constructed with the TruSeq ChIP Sample Prep kit
from lllumina. Libraries underwent a final amplification step of 15 PCR cycles
and were analyzed using a Bioanalyzer with a high-sensitivity chip (Agilent).
Libraries were single-end sequenced on a HiSeq2000 with reads of 50 bp.
A full description can be found in the Supplemental Experimental Proce-
dures section.
ACCESSION NUMBERS
The accession number for the raw and processed sequencing data reported in
this paper is GEO: GSE74651, with the subseries accession numbers GEO:
GSE74536 and GEO: GSE78221 (ChIP-seq) and GEO: GSE74650 and GEO:
GSE78224 (RNA-seq).Occupancy and Reduced Pol II Elongation at the Myc Locus
atment with DMSO or with 500 nM JQ1.
tment with DMSO or 500 nM JQ1.
tment with DMSO or with 500 nM JQ1.
ith DMSO or with 500 nM JQ1. Numbers above +14-bp and +3,965-bp regions
r 48-hr induction of shMed12 with doxycycline (dox). TRMPV-Neo vector was
r induction of shMed12 with dox. TRMPV-Neo vector was used.
induction of shMed12 with dox. TRMPV-Neo vector was used.
induction of shMed12 with dox. Numbers above +14 bp and +3,965 bp data
V-Neo vector was used. All experiments were performed in RN2 cells. All data
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